Technical analysis of Precision BioSciences, Inc. (DTIL): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases.
Price Performance
| 1 month | -19.44% |
| 3 months | -2.64% |
| Year-to-date | +59.37% |
| 1 year | +46.36% |
| 3 years | -46.14% |
| 5 years | -98.28% |
52-Week Range
| 52-week High | $9.62 |
| 52-week Low | $3.53 |
| Avg Volume (90d) | 378K |
Technical Indicators
| SMA 50 | $7.71 |
| SMA 200 | $6.23 |
| Beta | 1.09 |
| 30-day Volatility (annualised) | 48.5% |
| Price vs SMA 50 | -14.0% |
| Price vs SMA 200 | +6.5% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $8.16 | |
| 2025-11 | $5.44 | -33.3% |
| 2025-12 | $4.16 | -23.5% |
| 2026-01 | $3.96 | -4.8% |
| 2026-02 | $4.20 | +6.1% |
| 2026-03 | $5.50 | +31.0% |
| 2026-04 | $7.15 | +30.0% |
| 2026-05 | $6.97 | -2.5% |
| 2026-06 | $7.86 | +12.8% |
| 2026-07 | $6.99 | -11.1% |
| 2026-08 | $7.64 | +9.3% |
| 2026-09 | $6.63 | -13.2% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | $144M |
| 2026-09-14 | | $898M |
Price
| Price | $6.63 |
| Market Cap | $85M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.78 |
| EV / EBITDA | -0.76 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.62 |
| Current Ratio | 12.82 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -4.31 |